Lipopolysaccharide-induced cytokine cascade and lethality in LTα/TNFα- deficient mice

Molecular Medicine

Volumn 3, Issue 12, 1997, Pages 864-875

  Amiot, Franck ^a   Fitting, Catherine ^b   Tracey, Kevin J ^c   Cavaillon, Jean Marc ^b   Dautry, François ^a  

^a Institute de Recherche sur le Cancer   (France)

^b INSTITUT PASTEUR   (France)

^c PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; SEMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; FEMALE; GENOTYPE; IMMUNOASSAY; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPTIC SHOCK;

EID: 0031431016     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401722     Document Type: Article

References (72)

1. Smith DM, Lackides GA, Epstein LB. (1990) Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity. Cancer Res. 50: 3146-3153.
2. Van Damme J, Opdenakker G, Simpson RJ, et al. (1987) Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp. Med. 165: 914-919.
3. Cassatella MA, Guasparri I, Ceska M, Bazzoni F, Rossi F. (1993) Interferon-gamma inhibits interleukin-8 production by human polymorphonuclear leucocytes. Immunology 78: 177-184.
4. Wanidworanum C, Strober W. (1993) Predominant role of tumor necrosis factor-α in human monocyte IL-10 synthesis. J. Immunol. 151: 6853-6861.
5. Yamada H, Iwase S, Mohri M, Kufe D. (1991) Involvement of a nuclear factor-λB-like protein in induction of the macrophage colony stimulating factor gene by tumor necrosis factor. Blood 178: 1988-1995.
6. Debs RJ, Fuchs HJ, Philip R, et al. (1988) Lung-specific delivery of cytokines induces sustained pulmonary and systemic immunomodulation in rats. J. Immunol. 140: 3482-3488.
7. Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W. (1989) Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J. Exp. Med. 169: 2257-2262.
8. Sheron N, Williams R. (1992) IL-8 as a circulating cytokine: Induction by recombinant tumour necrosis factor-alpha. Clin. Exp. Immunol. 89: 100-103.
9. van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJ. (1994) Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J. Exp. Med. 180: 1985-1988.
10. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA. (1992) Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha. J. Immunol. 149: 1666-1670.
11. Michie H, Manogue K, Spriggs D, et al. (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318: 1481-1486.
12. Cannon J, Tompkins R, Gelfand J. (1990) Circulating interleukin 1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J. Infect. Dis. 161: 79-84.
13. Redl H, Schlag G, Bahrami S, Schade U, Ceska M, Stutz P. (1991) Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model. J. Infect. Dis. 164: 383-388.
14. Martich GD, Danner RL, Ceska M, Suffredini AF. (1991) Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents. J. Exp. Med. 173: 1021-1024.
15. Wollenberg GK, DeForge LE, Bolgos G, Remick DG. (1993) Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am. J. Pathol. 143: 1121-1130.
16. Fong Y, Tracey KJ, Moldawer LL, et al. (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170: 1627-1633.
17. Emerson T, Jr, Lindsey DC, Jesmok GJ, Duerr ML, Fournel MA. (1992) Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ. Shock 38: 75-84.
18. Teti G, Mancuso G, Tomasello F, Chiofalo MS. (1992) Production of tumor necrosis factor-alpha and interleukin-6 in mice infected with group B streptococci. Circ. Shock 38: 138-144.
19. Hinshaw LB, Emerson T, Jr, Taylor F Jr, et al. (1992) Lethal Staphylococcus aureus-induced shock in primates: Prevention of death with anti-TNF antibody. J. Trauma 33: 568-573.
20. van der Poll T, Levi M, van Deventer SJ, et al. (1994) Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83: 446-451.
21. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U.S.A. 89: 4845-4849.
22. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J. Immunol. 155: 5038-5045.
23. Espat NJ, Cendan JC, Beierler EA, et al. (1995) PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J. Surg. Res. 59: 153-158.
24. Teti G, Mancuso G, Tomasello F. (1993) Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect. Immun. 61: 227-235.
25. Junger WG, Hoyt DB, Redl H, et al. (1995) Tumor necrosis factor antibody treatment of septic baboons reduces the production of sustained T-cell suppressive factors. Shock 3: 173-178.
26. Ferran C, Dautry F, Merite S, et al. (1994) Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J. Clin. Invest. 93: 2189-2196.
27. Cavaillon JM, Marie C, Pitton C, Fitting C. (1995) The production of TNF alpha and IL-8 in whole blood assays are differently regulated upon activation by LPS. Prog. Clin. Biol. Res. 392: 433-439.
28. Vasilescu C, Berger D, Buttenschön K, Seidelmann M, Beger HG. (1996) Endotoxin-induced release of interleukin-6 and interleukin-1β in human blood is independent of tumor necrosis factor-α. Eur. Surg. Res. 28: 55-62.
29. Schandené L, Vandenbussche P, Crusiaux A, et al. (1992) Differential effects of pentoxifylline on the production of tumor necrosis factor alpha and interleukin-6 by monocytes and T cells. Immunology 76: 30-34.
30. Mandi Y, Farkas G, Ocsovszky I, Nagy Z. (1995) Inhibition of tumor necrosis factor production and ICAM-1 expression by pentoxifylline: Beneficial effects in sepsis syndrome. Res. Exp. Med. 195: 297-307.
31. Netea MG, Blok WL, Kullberg BJ, et al. (1995) Pharmocologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J. Infect. Dis. 171: 393-399.
32. Amiot F, Bellkaid Y, Lebastard M, Ave P, Dautry F, Milon G. (1996) Abnormal organisation of the splenic marginal zone and the correlated leukocytosis in lymphotoxin-α and tumor necrosis factor-α double deficient mice. Eur. Cytokine Netw 7: 733-739.
33. Amiot F, Boussadia O, Cases S, et al. (1997) Mice heterozygous for a deletion of the TNFα and LTα genes: Biological importance of a non linear response of TNFα dosage. Eur. J. Immunol. 27: 1035-1042.
34. Beutler B, Milsark IW, Cerami AC. (1985) Passive immunization against cahectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871.
35. Tracey KJ, Fong Y, DG. H, et al. (1987) Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662-664.
36. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA. (1992) Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J. Lab. Clin. Med. 120: 574-588.
37. Jesmok G, Lindsey C, Duerr M, Fournel M, Emerson Jr, T. (1992) Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli challenged swine. Am. J. Pathol. 141: 1197-1207.
38. Freudenberg MA, Galanos C. (1991) Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59: 2110-2115.
39. Franks AK, Kujawa KI, Yaffe LJ. (1991) Experimental elimination of tumor necrosis factor in low-dose endotoxin models has variable effects on survival. Infect. Immun. 59: 2609-2614.
40. Rothe J, Lesslauer W, Löscher H, et al. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802.
41. Abraham E, Wunderink R, Silverman H, et al. (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273: 934-941.
42. Fisher CJ, Agosti JM, Opal SM, et al. (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N. Engl. J. Med. 334: 1697-1702.
43. Sansonetti PJ, Arondel J, Cavaillon JM, Huerre M. (1995) Role of interleukin-1 in the pathogenesis of experimental shigellosis. J. Clin. Invest. 96: 884-892.
44. Bianchi M, Bloom O, Raabe T, et al. (1996) Suppression of pro-inflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J. Exp. Med. 183: 927-936.
45. Firenstein GS, Boyle D, Bullough DA, et al. (1994) Protective effect of an adenosine kinase inhibitor in septic shock. J. Immunol. 152: 5853-5859.
46. Marino MW, Dunn A, Grail D, et al. (1997) Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94: 8093-8098.
47. Hinson R, Williams JA, Shacter E. (1996) Elevated interleukin-6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2. Proc. Natl. Acad. Sci. U.S.A. 93: 4885-4890.
48. Sower LE, Froelich CJ, Carney DH, Fenton II, JW, Klimpel GR. (1995) Thrombin induces IL-6 productin in fibroblasts and epithelial cells. J. Immunol. 155: 895-901.
49. Thivierge M, Rola-Pleszczynsky M. (1992) Platelet activating factor enhances interleukin-6 production by alveolar macrophages. J. Allergy Clin. Immunol. 90: 796-802.
50. Brach MA, de Vos S, Arnold C, Gruß H-J, Mertelsmann R, Herrmann F. (1992) Leukotriene B4 transcriptionally activates interleukin-6 expression involving NF-κB and NF-IL6. Eur. J. Immunol. 22: 2705-2711.
51. Musso T, Espinoza-Delgado I, Pulkki K, Gusella GL, Longo DL, Varesio L. (1992) IL-2 induces IL-6 production in human monocytes. J. Immunol. 148: 795-800.
52. Schmidt JA, Abdulla E. (1988) Down-regulation of IL-1β biosynthesis by inducers of the heat shock response. J. Immunol. 141: 2027-2034.
53. Snyder DS, Unanue ER. (1982) Corticosteroids inhibit murine macrophage Ia expression and interleukin-1 production. J. Immunol. 129: 1803-1805.
54. Fushimi T, Okayama H, Seki T, Shimura S, Shirato K. (1997) Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral blood mononuclear cells and monocytes. Int. Arch. Allergy Immunol. 112: 13-18.
55. Barsig J, Küsters S, Vogt K, Volk HD, Tiegs G, Wendel A. (1995) Lipopolysaccharide-induced interleukin-10 in mice: Role of endogenous tumor necrosis factor-α. Eur. J. Immunol. 25: 2888-2893.
56. De Forge LE, Kenney JS, Jones ML, Warren JS, Remick DG. (1992) Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. Separation of LPS- and cytokine-stimulated components using anti-tumor necrosis factor and anti-IL-1 antibodies. J. Immunol. 148: 2133-2141.
57. Gearing AJH, Beckett P, Christodoulou M, et al. (1994) Processing of tumour necrosis factor-α precursor by metalloproteinase. Nature 370: 555-557.
58. McGeehan GM, Becherer JD, Bast Jr, RC, et al. (1994) Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 370: 558-561.
59. Lesslauer W, Tabuchi H, Gentz R, et al. (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from LPS-induced lethality. Eur. J. Immunol. 21: 2883-2886.
60. Ashkenazi A, Marsters S, Capon D, et al. (1991) Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc. Natl. Acad. Sci. U.S.A. 88: 10535-10539.
61. Mohler KM, Torrance DS, Smith CA, et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151: 1548-1561.
62. Silva A, Bayston K, Cohen J. (1990) Prophylactic and theurapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental Gram negative shock. J. Infect. Dis. 161: 1148-1152.
63. Martin RA, Silva AT, Cohen J. (1993) Effect of anti-TNF-alpha treatment in an antibiotic treated murine model of shock due to Streptococcus pyogenes. FEMS Microbiol. Lett. 110: 175-178.
64. Eugster HP, Muller M, Karrer U, et al. (1996) Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice. Int. Immunol. 8: 23-26.
65. Ohlsson K, Bjökk P, Bergenfield M, Hageman R, Thompson R. (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550-552.
66. Block MI, Berg M, McNamara MJ, Norton JA, Fraker DL, Alexander HR. (1993) Passive immunization of mice against D factor blocks lethality and cytokine release during endotoxemia. J. Exp. Med. 178: 1085-1090.
67. Bernhagen J, Calandra T, Mitchell RA, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
68. Cohen PS, Nakshatri H, Dennis J, et al. (1996) CN1-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc. Natl. Acad. Sci. U.S.A. 93: 3967-3971.
69. Bianchi M, Ulrich P, Bloom O, et al. (1995) An inhibitor of macrophage arginine transport and nitric oxyde production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med. 1: 254-266.
70. Erickson SL, de Sauvage F, Kikly K, et al. (1994) Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372: 560-563.
71. Pfeffer K, Matsuyama T, Kundig TM, et al. (1993) Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467.
72. Garcia I, Miyazaki Y, Araki K, et al. (1995) Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur. J. Immunol. 25: 2401-2407.